Skip to main content

Table 2 Selective patient and tumor characteristics

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

  E-T-CMF E-CMF Analyzed cohort
  (N = 159) (N = 193) (N = 352)
  Median Range Median Range Median Range
Age (in years) 50.2 23.8-75.9 50.6 22.5-78.0 50.6 22.5-78.0
Number of nodes removed 19 5-59 19 4-53 19 4-59
Number of positive nodes 7 0-54 6 0-49 6 0-54
  N % N % N %
Nodal involvement (n = 352)       
   0-3 nodes 34 21.4 54 28.0 88 25.0
   ≥ 4 nodes 125 78.6 139 72.0 264 75.0
Menopausal status (n = 352)       
   Premenopausal 83 52.2 104 53.9 187 53.1
   Postmenopausal 76 47.8 89 46.1 165 46.9
Type of operation (n = 352)       
   Modified radical mastectomy 122 76.7 151 78.2 273 77.6
   Breast conserving surgery 37 23.3 42 21.8 79 22.4
Interval from operation (n = 352)       
   < 2 weeks 19 11.9 26 13.5 45 12.8
   2-4 weeks 81 50.9 84 43.5 165 46.9
   > 4 weeks 59 37.1 83 43.0 142 40.3
Tumor grade* (n = 351)       
   I-II 64 40.5 112 58.0 176 50.1
   III-Undifferentiated 94 59.5 81 42.0 175 49.9
Tumor size (n = 352)       
   < 2 cm 45 28.3 67 34.7 112 31.8
   2-5 cm 88 55.3 91 47.2 179 50.9
   > 5 cm 26 16.4 35 18.1 61 17.3
Adjuvant RT (n = 350)       
   No 27 17.1 39 20.3 66 18.9
   Yes 131 82.9 153 79.7 284 81.1
Adjuvant HT (n = 351)       
   No 12 7.6 21 10.9 33 9.4
   Yes 146 92.4 172 89.1 318 90.6
ER protein status (n = 306)       
   Negative 40 28.2 41 25.0 81 26.5
   Positive 102 71.8 123 75.0 225 73.5
PgR protein status (n = 305)       
   Negative 52 36.6 54 33.1 106 34.8
   Positive 90 63.4 109 66.9 199 65.2
Hormone receptor status (n = 307)       
   Negative 36 25.4 29 17.6 65 21.2
   Positive 106 74.6 136 82.4 242 78.8
Ki67 (n = 309)       
   Low (< 14%) 25 17.4 30 18.2 55 17.8
   High (≥ 14%) 119 82.6 135 81.8 254 82.2
HER2 CISH amplification (n = 285)       
   Non-amplified 100 75.2 121 79.6 221 77.5
   Amplified 33 24.8 31 20.4 64 22.5
HER2 mRNA expression (n = 314)       
   Low (< 75th percentile) 108 75.0 128 75.3 236 75.2
   High (≥ 75th percentile) 36 25.0 42 24.7 78 24.8
HER2 protein expression (n = 297)**       
   0-1+ 86 63.2 125 77.6 211 71.0
   2+ 19 14.0 15 9.3 34 11.4
   3+ 31 22.8 21 13.0 52 17.5
TOP2A CISH amplification (n = 266)       
   Non-amplified 110 90.9 137 94.5 247 92.9
   Amplified 11 9.1 8 5.5 19 7.1
TOP2A mRNA expression (n = 314)       
   Low (< median) 72 50.0 85 50.0 157 50.0
   High (≥ median) 72 50.0 85 50.0 157 50.0
TopoIIa protein status (n = 273)       
   Negative 43 35.2 56 37.1 99 36.3
   Positive 79 64.8 95 62.9 174 63.7
  1. *: p = 0.001; **: p = 0.023; The distribution of grade and HER2 protein expression differs significantly between the two groups.
  2. RT. radiotherapy; HT. hormonotherapy; CISH. chromogenic in situ hybridization.